文献速递炎症性肠病

乌司奴单抗继发失应答后剂量强化对克罗恩病的疗效:REScUE研究结果

The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study.
PubMed 文献 · Gastroenterology · 2026-02-24

REScUE研究是在比利时15家医院开展的多中心随机对照试验,纳入108例接受乌司奴单抗90 mg每8周维持治疗但出现继发失应答的克罗恩病患者。患者随机接受单次静脉再诱导后分别以90 mg每4周或每8周皮下给药至48周,第48周无激素临床缓解率分别为15%与19%(差异4%,P=0.5),强化方案未显示更优。

要点

  • 乌司奴单抗继发失应答的克罗恩病患者中,每4周皮下强化并不优于每8周给药。
  • 第48周无激素临床缓解率每4周组15%、每8周组19%,差异无统计学意义。
  • 严重不良事件发生率每4周组17%、每8周组13%。

核心结论

  • 在克罗恩病乌司奴单抗继发失应答患者中,单次静脉再诱导后每4周皮下给药并不比每8周给药更有效。

研究设计与样本

  • 研究者发起、多中心、随机、安慰剂对照试验,在比利时15家医院开展,共随机108例患者。

主要发现

  • 第48周无激素临床缓解率每4周组为15%,每8周组为19%(差异4%,P=0.5)。
  • 严重不良事件发生率每4周组为17%,每8周组为13%。

关键数值与推荐

  • 入组患者为接受乌司奴单抗90 mg皮下每8周维持治疗且出现继发失应答的成人克罗恩病患者。
  • 无激素临床缓解定义为患者报告结局2缓解(腹痛≤1且排便频率≤3)且粪钙卫蛋白<250 μg/g且第48周前90天内未使用激素。
  • 随机分组为单次静脉再诱导约6 mg/kg后,皮下乌司奴单抗90 mg每4周或每8周至第48周。

临床怎么用

  • 对于乌司奴单抗继发失应答的克罗恩病患者,单次静脉再诱导后每4周皮下强化方案未显示优于每8周方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Secondary loss of response to ustekinumab is observed in patients with Crohn's disease (CD). Multiple dose-intensification regimens have been proposed. We aimed to test prospectively 2 different dose-intensification regimens with ustekinumab in patients with CD experiencing secondary loss of response. METHODS: This was an investigator-initiated, multicenter, randomized, placebo-controlled trial conducted at 15 hospitals in Belgium. Eligible patients were adults with CD treated with ustekinumab on maintenance dosing of 90 mg subcutaneous every 8 weeks and experiencing a secondary loss of response (Patient-Reported Outcomes 2: abdominal pain score >1 and liquid or very soft stool frequency >3 and an objective documentation of disease). Patients were randomized 1:1 to receiving a single intravenous reinduction with ustekinumab ≈6 mg/kg followed by either subcutaneous ustekinumab 90 mg every 4 weeks or every 8 weeks until week 48. The primary endpoint was the proportion of patients with steroid-free clinical remission at week 48, defined as Patient-Reported Outcomes 2 remission: (abdominal pain ≤ 1 and stool frequency ≤3) and fecal calprotectin <250 μg/g and no steroids in the 90 days before week 48. RESULTS: Between March 2020 and October 2023, 108 patients were randomized. Steroid-free clinical remission at week 48 was reached in 15% vs 19% of patients in the every 4 weeks vs the every 8 weeks group (difference 4%; P = 0.5). Serious adverse events occurred in 17% vs 13% of patients. CONCLUSIONS: In patients with CD and secondary loss of response to ustekinumab, dose intensification with a single intravenous administration and followed by 4 weekly subcutaneous dosing of ustekinumab was not more effective than 1 intravenous administration followed by 8 weekly subcutaneous dosing of ustekinumab. (ClinicalTrials.gov, Number: NCT04245215).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bossuyt P, Rahier JF, Baert F, et al. The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn's Disease: Results of the REScUE Study. Gastroenterology. 2026. PMID: 41747777. doi:10.1053/j.gastro.2026.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。